German Real Estate Stock News

XTRA:CON
XTRA:CONAuto Components

Continental (XTRA:CON) TTM Loss Of €445 Million Tests Bullish Profitability Narratives

Continental FY 2025 earnings snapshot Continental (XTRA:CON) has wrapped up FY 2025 with fourth quarter revenue of €4,965 million and net income from continuing operations of €13 million, while earnings from discontinued operations contributed €4 million. The company has seen quarterly revenue shift from €10,095 million in Q4 2024 to around the €4,856 million to €4,965 million range across 2025, with Basic EPS moving from €2.15 in Q4 2024 to readings between a loss of €3.78 in Q3 2025 and a...
XTRA:SAX
XTRA:SAXMedia

Ströer SE KGaA (XTRA:SAX) Margin Uptick Tests Bullish Earnings Growth Narrative

Ströer SE KGaA (XTRA:SAX) has wrapped up FY 2025 with fourth quarter revenue of €603.3 million and net income of €65 million, setting the tone for how investors read the year as a whole. Over recent quarters the company has seen revenue move from €475.5 million in Q1 2025 to €504.7 million in Q2 and €491.5 million in Q3. Trailing twelve month revenue sits at about €2.1 billion and net income at €140 million, giving helpful context around the most recent print. With net profit margin at 6.7%...
XTRA:MBG
XTRA:MBGAuto

Mercedes Benz Group (XTRA:MBG) Margin Compression Challenges Bullish Earnings Growth Narrative

Mercedes-Benz Group (XTRA:MBG) FY 2025 earnings snapshot Mercedes-Benz Group (XTRA:MBG) has wrapped up FY 2025 with fourth quarter revenue of €33.7b and basic EPS of €1.43, backed by net income of €1.4b. The company has seen quarterly revenue move from €38.5b and EPS of €2.57 in Q4 2024 to €33.7b and €1.43 in Q4 2025, with FY 2025 quarters ranging between €32.1b and €33.7b of revenue and EPS between €0.95 and €1.74. With trailing net margin sitting at 3.9% versus 7% a year earlier, this set...
XTRA:BAYN
XTRA:BAYNPharmaceuticals

Bayer (XTRA:BAYN) Q4 Loss Of €3.8b Tests Earnings Turnaround Narrative

Bayer FY 2025 earnings snapshot Bayer (XTRA:BAYN) has capped FY 2025 with a tough final quarter, posting Q4 revenue of €11.4 billion and a basic EPS loss of €3.80, alongside a net loss of €3.8 billion. Over recent periods, the company has seen quarterly revenue move between €9.7 billion and €13.7 billion, while EPS has swung from a profit of €1.32 in Q1 2025 to losses in each of the following quarters. This keeps the focus firmly on how quickly margins can stabilize. With forecasts in the...
XTRA:SY1
XTRA:SY1Chemicals

Assessing Symrise (XTRA:SY1) Valuation After Results, Dividend Increase, Buyback And Care And Wellness Launch

Symrise (XTRA:SY1) shares are in focus after the company paired its 2025 results with a proposed dividend increase, a new Care & Wellness division, and a €400 million share buyback program. See our latest analysis for Symrise. At a share price of €72.68, Symrise has a 1-day share price return of 2.45% and a year to date share price return of 6.32%. However, the 1-year total shareholder return of 23.13% and 5-year total shareholder return of 24.66% show that longer term holders have faced...
XTRA:SIX2
XTRA:SIX2Transportation

A Look At Sixt (XTRA:SIX2) Valuation After Record 2025 Results And Higher Dividend Proposal

Sixt (XTRA:SIX2) has moved into focus after reporting 2025 earnings, with sales of €4,282.98m and net income of €285.81m, alongside a proposed 18.5% dividend increase. See our latest analysis for Sixt. The 1-day share price return of 4.34% to €67.25 comes after record 2025 results. However, the 1-year total shareholder return of a 21.46% decline and the 3-year total shareholder return of a 39.08% decline suggest momentum has been fading despite recent earnings strength. If this earnings news...
XTRA:LEG
XTRA:LEGReal Estate

LEG Immobilien (XTRA:LEG) One Off Gain Drives Net Margin And Tests Bearish Narratives

LEG Immobilien (XTRA:LEG) has wrapped up FY 2025 with Q4 revenue of €397.3 million and basic EPS of €4.37, while its trailing twelve month figures sit at €1.58 billion of revenue and EPS of €19.44. Over recent periods, revenue has moved from €515.6 million in Q4 2024 to €468.7 million in Q1 2025, €361.7 million in Q2, €351.4 million in Q3 and €397.3 million in Q4, with quarterly EPS ranging from €0.77 to €9.08. As a result, investors are likely to focus on how these swings and the very high...
XTRA:HAG
XTRA:HAGAerospace & Defense

A Look At Hensoldt (XTRA:HAG) Valuation After Raised 2026 Guidance And Higher Dividend Proposal

Hensoldt (XTRA:HAG) is back in focus after raising its 2026 earnings guidance, with the company now targeting around €2,750 million in revenue, along with a higher annual dividend proposal and renewed leadership commitment. See our latest analysis for Hensoldt. Despite the raised 2026 guidance and higher dividend proposal, Hensoldt’s recent news flow has coincided with pressure on the share price. A 1 month share price return of 10.69% and a 7 day share price return of 6.26% indicate that...
XTRA:MRK
XTRA:MRKPharmaceuticals

Assessing Merck KGaA (XTRA:MRK) Valuation After Latest Earnings And Life Science Growth

Merck KGaA (XTRA:MRK) is back in focus after reporting fourth quarter and full year 2025 results. The latest sales and earnings figures give investors fresh data on its Life Science, Healthcare and Electronics segments. See our latest analysis for Merck KGaA. The earnings release appears to have reset expectations, with a 1-day share price return of an 8% decline and a 1-year total shareholder return of an 18.41% decline, indicating that pressure has been building rather than easing. If Merck...
XTRA:DHL
XTRA:DHLLogistics

Has The Recent Pullback In Deutsche Post (XTRA:DHL) Opened A Fresh Valuation Opportunity?

If you are wondering whether Deutsche Post's current share price still offers value or if most of the opportunity is already priced in, you are exactly who this review is written for. The stock last closed at €45.89, with a 7.9% decline over the past week and a 5.1% decline over the past month, while the 1 year and 3 year returns sit at 8.9% and 27.5% respectively. Recent news coverage has focused on Deutsche Post's role as a major global logistics and parcel provider, with attention on how...
XTRA:VOW3
XTRA:VOW3Auto

Volkswagen Dealers Challenge Scout Motors Direct Sales Model In Court

Volkswagen (XTRA:VOW3) is facing a new class-action lawsuit in the U.S. filed by a group of its franchised dealerships. The dealers allege the company breached existing agreements by using Scout Motors to sell electric vehicles directly to consumers. The case centers on whether Scout branded EVs should pass through the traditional dealer model or a separate direct to consumer channel. For you as an investor, this dispute sits at the intersection of legacy auto retail models and newer direct...
XTRA:GYC
XTRA:GYCReal Estate

Grand City Properties FY 2025 One Off Boost Tests Bullish Re Rating Narrative

Grand City Properties FY 2025 earnings snapshot Grand City Properties (XTRA:GYC) has wrapped up FY 2025 with Q4 revenue of €149.9 million and basic EPS of €0.79, set against a trailing twelve month net income of €511.9 million and EPS of €2.67. Over the past year, the company has seen revenue move from €597.0 million to €601.5 million on a trailing basis, while EPS shifted from €1.14 to €2.67, alongside a net profit margin of 85.1% that is influenced by a €272.5 million one off gain...
XTRA:ADS
XTRA:ADSLuxury

Adidas (XTRA:ADS) Margin Reset To 5.4% Challenges Long Term Earnings Slump Narrative

Adidas (XTRA:ADS) has just wrapped up FY 2025 with fourth quarter revenue of €6.1b and basic EPS of €0.42, capping a year in which trailing twelve month revenue reached €24.8b and EPS came in at €7.46. Over recent periods, quarterly revenue has ranged from €5.7b to €6.7b while basic EPS moved from a loss of €0.26 in Q4 2024 to €2.56 in Q3 2025, alongside trailing net profit margin of 5.4% and earnings growth of 76.2% over the last year. This sets up a results season in which investors are...
XTRA:AFX
XTRA:AFXMedical Equipment

Can ZEISS (XTRA:AFX) Turn New Collaborative Care Software Into a Lasting Digital Moat?

In February 2026, ZEISS Medical Technology launched ZEISS Collaborative Care, a browser-based, cloud-delivered application that lets eye care professionals securely share diagnostic data, manage referrals, and communicate in real time across different clinical settings. By sitting on the ZEISS Healthcare Data Platform and linking with ZEISS FORUM, the software effectively turns existing ophthalmic devices and data silos into a connected collaboration network for more coordinated care. We’ll...
XTRA:AT1
XTRA:AT1Real Estate

Aroundtown (XTRA:AT1) One Off Boost To 55.9% Margin Tests Bullish Profit Narrative

Aroundtown (XTRA:AT1) has wrapped up FY 2025 with fourth quarter revenue of €396 million and basic EPS of €0.14, alongside trailing twelve month revenue of about €1.6 billion and EPS of €0.61. Together, these figures frame a year of sharp earnings recovery from a much weaker prior period. Over recent quarters, the company has seen revenue move from €352.1 million and EPS of €0.25 in Q4 2024 through to €390.7 million and EPS of €0.20 in Q1 2025, with Q3 2025 landing at €389.9 million and EPS...
XTRA:DEZ
XTRA:DEZMachinery

DEUTZ (XTRA:DEZ) Is Down 8.1% After Drone Defence Pivot And BlackRock Stake Rise Has The Bull Case Changed?

Recently, TYTAN Technologies announced a partnership and funding round with DEUTZ, under which DEUTZ will supply and industrialise drive, battery, and energy modules for TYTAN’s drone defence systems, while also preparing to showcase its sustainable drive and energy solutions at CONEXPO Las Vegas. This move marks DEUTZ’s entry into the European unmanned defence systems market and coincides with BlackRock increasing its voting stake above the 3% threshold, highlighting growing institutional...
XTRA:BAYN
XTRA:BAYNPharmaceuticals

Bayer Litigation Deal And Cancer Data Reframe Risk Reward For Investors

Bayer received preliminary court approval for a multibillion euro Roundup class action settlement, addressing a large portion of ongoing litigation. The company reported positive late stage clinical data in prostate cancer, including survival benefits for radium 223 (XOFIGO) in combination therapy and first in human data for a next generation targeted alpha therapy. The FDA cleared expanded capabilities for Bayer's MEDRAD MRXperion MR injection system in the United States. Bayer entered an...
XTRA:BAS
XTRA:BASChemicals

Assessing BASF (XTRA:BAS) Valuation As Shares Show Short Term Momentum But Weaker One Year Return

Why BASF (XTRA:BAS) Is Back on Investors’ Radar BASF (XTRA:BAS) has moved back into focus for some investors after a period of mixed share performance, with a slight gain over the past 3 months and a negative 1 year total return. This combination of recent improvement alongside a weaker 1 year result is prompting closer attention to how the chemical group’s current valuation lines up with its earnings, cash generation, and long established global footprint. See our latest analysis for...
XTRA:DWS
XTRA:DWSCapital Markets

A Look At DWS Group (XTRA:DWS) Valuation After Rising Geopolitical Tensions Involving Iran

Geopolitical shock puts focus on DWS Group GmbH KGaA (XTRA:DWS) A joint U.S. and Israeli strike on Iran has pushed geopolitical risk higher and sharpened market attention on oil prices, safe-haven flows, and volatility in risk assets, including asset managers such as DWS Group GmbH KGaA (XTRA:DWS). See our latest analysis for DWS Group GmbH KGaA. At around €58.35, DWS Group’s recent 1-day share price return of 1.92% comes after a 30-day share price return decline of 6.79%. Its 1-year total...
XTRA:SAP
XTRA:SAPSoftware

A Look At SAP (XTRA:SAP) Valuation After AI-Focused Executive Reorganization

SAP (XTRA:SAP) has reshaped its leadership around artificial intelligence, creating a new Customer Value Group under Chief Customer Officer Thomas Saueressig to align sales, services and support and push adoption of its cloud and AI products. See our latest analysis for SAP. Despite the leadership reshuffle and a busy run of announcements, including the Teradata legal settlement, updated bonus framework and a proposed dividend of €2.50 per share, SAP’s recent share price performance has been...
XTRA:EOAN
XTRA:EOANIntegrated Utilities

A Look At E.ON (XTRA:EOAN) Valuation After 2025 Earnings And Higher Dividend Proposal

E.ON (XTRA:EOAN) has drawn fresh attention after reporting full year 2025 earnings and proposing a higher dividend of €0.57 per share, a 4% increase, despite lower sales and net income. See our latest analysis for E.ON. The proposed dividend increase and the recent earnings release come after a strong run in E.ON’s shares, with a 90 day share price return of 21.11% and a 1 year total shareholder return of 60.64%. This suggests momentum has been building even as reported net income moved lower...
XTRA:RWE
XTRA:RWERenewable Energy

RWE Fusion Alliance Adds Long Term Optionality To Valuation Debate

RWE (XTRA:RWE) has entered into an agreement with Proxima Fusion, the Max Planck Institute and the State of Bavaria to commercialize fusion energy in Europe. The partners plan to work toward building what they aim to be the world's first commercial stellarator fusion power plant. The alliance focuses on moving fusion technology from research settings into industrial scale deployment in Europe. RWE shares most recently traded at €53.34, with the stock up 13.7% year to date and 81.0% over the...
XTRA:ALV
XTRA:ALVInsurance

Allianz (XTRA:ALV) Valuation Check After Earnings Beat, Higher Dividend, 2026 Guidance And €2.5b Buyback

Allianz (XTRA:ALV) is in focus after reporting fourth quarter and full year 2025 earnings, proposing a higher dividend for 2025, issuing 2026 operating profit guidance, and confirming a new share buyback plan. See our latest analysis for Allianz. The latest earnings, higher proposed dividend and fresh €2.5b buyback come after a mixed period for the share price, with a 1 day share price return of 1.01% but a weaker 7 day move of 5.90% and a 30 day share price return of 5.33%. At the same time,...
XTRA:S92
XTRA:S92Electrical

A Look At SMA Solar Technology (XTRA:S92) Valuation After 2025 Results And Mixed Segment Performance

SMA Solar Technology (XTRA:S92) is back in focus after reporting 2025 results that showed a 0.9% sales decline, sharply lower EBITDA tied to impairments and restructuring, and contrasting performances across its core segments. See our latest analysis for SMA Solar Technology. The earnings update landed alongside a sharp 9.7% 1 day share price return to €32.0. However, the 30 day share price return of 11.0% and the year to date share price return of 10.5% point to fading momentum after a...